Randomized Trialhigh evidence
Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials.
Lancet (London, England)·October 23, 2026·PMID 42915009
Why it mattersRelapsing multiple sclerosis requires effective oral therapies with favorable safety. Remibrutinib, a CNS-penetrant BTK inhibitor, demonstrated superior relapse reduction versus an established oral disease-modifying therapy, with no liver safety concerns and fewer discontinuations, positioning it as a potential new first-line option.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled